Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.72 |
| ▸ | MEN1 | O00255 | 7/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | PARG | Q86W56 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470122 | 0.92 | GBA1 (1.00) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL8394068 | 0.85 | GBA1 (0.86) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL3811045 | 0.85 | GBA1 (0.86) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL14606609 | 0.84 | GBA1 (0.84) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL8396377 | 0.83 | GBA1 (0.83) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL7886816 | 0.83 | GBA1 (0.83) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL14518846 | 0.83 | GBA1 (0.71) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL4762339 | 0.83 | GBA1 (0.77) | GBA1KMT2AMEN1ALDH1A1PKM | |
| SCHEMBL4007108 | 0.82 | GBA1 (0.56) | GBA1KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL5205575 | 0.81 | GBA1 (0.79) | GBA1KMT2AMEN1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | GBA1 71/4885KMT2A 2886/4885MEN1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.